前列腺癌中的雄激素受体动态:从疾病进展到治疗耐药性
Caihong Li1, Dongkai Cheng1, Peng Li1
1Center for Reproductive Medicine, Shenyang Jinghua Hospital, Shenyang, China.
Frontiers in oncology
|February 26, 2025
概括
前列腺癌进展到由雄激素受体 (AR) 驱动的抵抗割的前列腺癌 (CRPC). 新疗法针对AR信号,表观遗传变化和瘤微环境来克服治疗耐药性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 前列腺癌是男性癌症死亡的主要原因,常常发展为抵抗割的前列腺癌 (CRPC).
- 雄激素受体 (AR) 是前列腺癌生长和治疗耐药性的关键驱动因素.
- 治疗耐药性源于AR的重新激活,表观遗传修饰和瘤微环境.
研究的目的:
- 审查割抵抗性前列腺癌 (CRPC) 进展的机制.
- 讨论针对雄激素受体 (AR) 途径的当前和未来治疗策略.
- 突出瘤微环境和前列腺癌治疗中的新型研究模型的作用.
主要方法:
- 关于前列腺癌进展和治疗抵抗机制的文献综述.
- 对雄激素受体 (AR) 信号传导,表观遗传变化和瘤微环境的作用的分析.
- 探索新兴的治疗目标和研究模型,包括有机体.
主要成果:
- 雄激素受体 (AR) 突变,放大和重新激活驱动CRPC进展和治疗失败.
- 表观遗传修饰和瘤微环境组件 (CAF,TAM) 导致侵袭性疾病和免疫逃避.
- 正在开发新的治疗策略来克服耐药性,包括下一代AR抗剂和免疫疗法组合.
结论:
- 了解AR信号传递,表观遗传调节和瘤微环境相互作用对于治疗晚期前列腺癌至关重要.
- 针对AR再激活和探索组合疗法有望改善患者的治疗结果.
- 像有机体这样的创新模型为研究前列腺癌和开发有效治疗方法提供了新的途径.
更多相关视频
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
10.5K
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.0K
相关概念视频
Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Internal Receptors
69.2K
Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.
69.2K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
